EC Number   |
Application |
Reference |
|---|
    6.3.1.2 | analysis |
immunoassay that detects synthetase protein samples where the enzyme has been inactivated by repeated cycles of freezing and thawing, and in serum and cerebrospinal fluid where glutamine synthetase is undetectable by the enzyme activity assay |
37568 |
| 6.3.1.2 | diagnostics |
glutamine synthetase is a useful marker in tumour liver pathology, including hepatocellular adenomas and nodules in cirrhosis. Enzyme overexpression in focal nodular hyperplasia can be used as easy diagnostic tool in surgical pathology |
693959 |
| 6.3.1.2 | drug development |
GlnA1 may not be a suitable target to find anti-tubercular drugs |
-, 744506 |
| 6.3.1.2 | drug development |
glutamine synthetase is a potential drug target in Mycobacterium tuberculosis |
-, 745816 |
| 6.3.1.2 | drug development |
inhibition of glutamine synthetase is one of the most promising strategies for the discovery of drugs against tuberculosis. The bone-targeting properties of the bisphosphonate compounds make them attractive agents for the treatment of bone tuberculosis |
-, 745460 |
| 6.3.1.2 | drug development |
the enzyme is a potential antimycobacterial drug target |
-, 691225 |
| 6.3.1.2 | drug development |
the enzyme is a target for design of structure-based specific inhibitors |
693624 |
| 6.3.1.2 | drug development |
the enzyme is an attractive target for development of antimycobacterial drugs |
-, 692709 |
| 6.3.1.2 | drug development |
the GSI-alpha-specific regulatory network can be exploited for inhibitor design against Gram-positive pathogens |
-, 727970 |
| 6.3.1.2 | medicine |
expression of glutathione synthetase is observed in 70% of hepatocellular carcinoma patients, 46.7% of chronic hepatitis B stage 4 patients and 38% of chronic hepatitis B stage 1-3 patients. There is significant difference between hepatocellular carcinoma samples and non-tumor tissues. Serum glutathione synthetase levels are increased in hepatocellular carcinoma and chronic hepatitis B stage 1-4 patients. There are significant differences among all samples, except chronic hepatitis B stage 1-3 versus chronic hepatitis B stage 4. Hepatocellular carcinoma, chronic hepatitis B stage 1-4 and AFP are significantly associated with serum glutathione synthetase levels. In hepatocellular carcinoma group, TNM and Child-Pugh are significantly associated with glutathione synthetase levels. Expression of glutathione synthetase is increased in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis B |
715144 |
